Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-JaCE03 for deep dermal burns
jRCT2052210214Completed
- Sponsor
- Japan Tissue Engineering Co., Ltd.
- Start
- Jun 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Allo-JaCE03 in deep second-degree burn, sponsored by Japan Tissue Engineering Co., Ltd. Primary endpoint: Epithelialization rate at day 7. Started Jun 2022; status: completed.
02
Drugs
Allo-JaCE03
03
Conditions
deep second-degree burn
Beyond the preview
Go deeper on jRCT2052210214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2052210214.